Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
159M
-
Number of holders
-
239
-
Total 13F shares, excl. options
-
87.3M
-
Shares change
-
-7.61M
-
Total reported value, excl. options
-
$2.17B
-
Value change
-
-$103M
-
Put/Call ratio
-
0.81
-
Number of buys
-
128
-
Number of sells
-
-97
-
Price
-
$24.84
Significant Holders of TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) as of Q2 2023
302 filings reported holding TGTX - TG THERAPEUTICS, INC. - COMMON STOCK as of Q2 2023.
TG THERAPEUTICS, INC. - COMMON STOCK (TGTX) has 239 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.3M shares
of 159M outstanding shares and own 54.98% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (13.5M shares), BlackRock Inc. (9.92M shares), Darwin Global Management, Ltd. (9.28M shares), FMR LLC (6.08M shares), STATE STREET CORP (5.63M shares), WELLINGTON MANAGEMENT GROUP LLP (3.16M shares), GEODE CAPITAL MANAGEMENT, LLC (2.83M shares), TWO SIGMA INVESTMENTS, LP (1.83M shares), MORGAN STANLEY (1.69M shares), and Holocene Advisors, LP (1.63M shares).
This table shows the top 239 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.